For HER2+ breast cancer patients, targeting HER2 using anti-HER2 monoclonal antibody drugs such as trastuzumab (TRZ, also known as herceptin) has been an attractive therapeutic approach [3]. The gene discussed is ERBB2; the disease is breast carcinoma.